In a significant regulatory setback for the Burman family-backed financial services firm, the Reserve Bank of India (RBI) has turned down Religare Enterprises Limited’s (REL) proposed corporate restructuring and demerger plan.
Key Takeaways from the Regulatory Filing
-
RBI Decision: In a formal regulatory submission, Religare Enterprises disclosed receiving a letter from the central bank stating that its request for a prior approval/no-objection certificate for the demerger scheme “has not been acceded to”. Religare Finvest Ltd (RFL), its subsidiary, received a similar communication.
-
Prior Clearances: The rejection comes despite the scheme securing approval from key stock market entities. The National Stock Exchange (NSE) had issued a ‘no objection’ letter, while the BSE Limited provided an observation letter with ‘no adverse observations’.
-
Management Response: Both REL and RFL stated they intend to actively engage with the central bank to seek further clarification and provide any required information to resolve the issue.
What Was the Proposed Restructuring?
The restructuring, approved by the company’s board in February, was aimed at creating two distinct, separately listed entities to unlock value and sharpen business focus:
-
Religare Enterprises Ltd (Parent Entity): Retaining its holdings in Care Health Insurance Ltd to operate strictly as an insurance-focused listed company.
-
Religare Finvest Ltd (Subsidiary): Taking over all financial services, including lending, broking, and investment operations, on a going-concern basis to act as an independent financial entity.
What Lies Ahead
While market regulator SEBI recently disposed of its previous show-cause proceedings involving the company and stock exchanges raised no objections, the central bank’s non-accession temporarily halts the company’s planned spin-off. Religare will need to address the RBI’s governance and regulatory concerns before any revised restructuring scheme can proceed.
